Pharma Focus Asia

RNA Therapeutics


Guillermo Tramontin and Cecilia Piergentili


While traditionally small molecules medicines and antibodies target specific proteins, RNA therapeutics target RNA molecules involved in disease processes, allowing for more precise and effective treatment. 

A key advantage of RNA therapeutics is the ability to target previously "undruggable" targets, such as transcription factors and non-coding RNAs, which are often involved in complex disease pathways. 

Additionally, RNA-based treatments can be designed to be highly selective and specific, reducing the risk of off-target effects and improving safety profiles (Winkler, 2021; Zhu et al. 2022). 

Development of these innovative therapies has been facilitated by technological advances and an understanding of RNA biology, including synthesizing and delivery of RNA molecules to specific tissues and cells in the body. 

Download '.pdf' Format of the whitepaper.

Download Whitepapers
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference